Melanoma Risk and Biologic Therapy: Is There a Link?
Because the TNF-α pathway plays a critical role in tumor surveillance, there is concern that inhibition of this pathway could predispose patients to certain malignancies.
Skin Cancer
SKIN CANCER
FEATURE ARTICLE
LATEST NEWS
Keytruda Approved for Cutaneous Squamous Cell Carcinoma
The FDA has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
Study Investigates Association Between Height and Risk for Invasive Melanoma
This study used data from the Nurses’ Health Study (NHS) and NHS2 to explore the association between height, number of nevi, and risk of invasive melanoma.
Specific Tumor Structures and Features Differentiate Sebaceous Carcinoma
The dermoscopic features and differential diagnosis in dermoscopic examination of sebaceous carcinoma are analyzed.
Advanced Melanoma Management in the COVID-19 Era
Strategies for the management of advanced melanoma during the coronavirus disease 2019 (COVID-19) pandemic are provided.
Racial Differences Seen in Time to Treatment for Melanoma
Black patients are more likely to experience a longer delay from diagnosis to surgery vs white patients with melanoma.
Melanoma Risk From Biologic Therapy Remains Uncertain
Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot be ruled out based on current evidence.
Exposure to Antibiotics Associated With Survival Detriment in Patients With Advanced Melanoma Treated With ICIs
Previous studies have shown an association between gut microbiome diversity and response to immune checkpoint inhibitor therapy.
FDG-PET Superior to CT for Predicting Melanoma Relapse After Immunotherapy
The long-term outcome of patients with melanoma may be predicted by FDG-PET imaging and also influence treatment duration.
PET, CT Scans for the Staging of Malignant Melanoma
Findings suggest that PET/CT imaging should be included in the malignant melanoma treatment algorithm starting with T2 patients.
Immunotherapy Is a Viable Treatment Strategy for Advanced MCC and CSCC
The frequent and durable responses to PD-1/PD-L1–blocking antibodies confirm the importance of immune mechanisms in nonmelanoma skin cancer pathogenesis.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Skin Cancer
